A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 71-76

  Kim, Hyeong Su ^a   Lee, Gyeong Won ^b,c,d   Kim, Jung Han ^a   Kim, Ho Young ^a   Kwon, Jung Hye ^a   Song, Hun Ho ^a   Kim, Hyo Jung ^a   Jung, Joo Young ^a   Jang, Geundoo ^a   Choi, Dae Ro ^a   Park, Sang Myeon ^a   Shin, Tae Rim ^a   Lee, Hee sung ^a   Zang, Dae Young ^a  

^a Hallym University Medical Center   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Gyeongnam Regional Cardiocerebrovascular Disease Center   (South Korea)

Author keywords

Carboplatin; Non small cell lung cancer; Pemetrexed; Salvage

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FOLIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FACE EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL RATE;

EID: 77956192118     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.12.015     Document Type: Article

References (28)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics. CA Cancer J Clin 2004, 54:8-29.
2. Shepherd F.A. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 1993, 5:310-322.
3. Non-small. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
4. Marino P., Pampallona S., Preatoni A., Cantoni A., Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994, 106:861-865.
5. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol 1993, 11:1866-1872.
6. Noble J., Ellis P.M., Mackay J.A., Evans W.K. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006, 1:1042-1058.
7. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
8. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354-2362.
9. Taylor E.C., Kuhnt D., Shih C., Rinzel S.M., Grindey G.B., Barredo J., et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992, 35:4450-4454.
10. Schultz R.M., Patel V.F., Worzalla J.F., Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate LY231514. Anticancer Res 1999, 19:437-443.
11. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
12. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
13. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:3852-3859.
14. Teicher B.A., Chen V., Shih C., Menon K., Forler P.A., Phares V.G., et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000, 6:1016-1023.
15. Zinner R.G., Fossella F.V., Gladish G.W., Glisson B.S., Blumenschein G.R., Papadimitrakopoulou V.A., et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005, 104:2449-2456.
16. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
17. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
19. Huang C.H., Millenson M.M., Sherman E.J., Borghaei H., Mintzer D.M., Cohen R.B., et al. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol 2008, 3:1032-1038.
20. Kosmas C., Tsavaris N., Vadiaka M., Stavroyianni N., Koutras A., Malamos N., et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001, 92:2902-2910.
21. Cobo M., Gutierrez V., Alcaide J., Ales I., Villar E., Gil S., et al. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer 2007, 56:255-262.
22. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
23. Smit E.F., Mattson K., von Pawel J., Manegold C., Clarke S., Postmus P.E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003, 14:455-460.
24. Bearz A., Garassino I., Cavina R., Favaretto A., Boccalon M., Talamini R., et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008, 60:240-245.
25. Smit E.F., Burgers S.A., Biesma B., Smit H.J., Eppinga P., Dingemans A.M., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:2038-2045.
26. Weiss G.J., Rosell R., Fossella F., Perry M., Stahel R., Barata F., et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18:453-460.
27. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
28. Peacock K.H., Lesser G.J. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 2006, 7:479-489.